Movement Alert｜INSILICO Rises 5.61% in Regular Trading, Life Sciences Sector Rally and Positive Pipeline Catalysts Boost Shares

Market Focus08-07

On August 7, INSILICO rose 5.61% in regular trading, trading at HK$43.5/share, with turnover of HK$325 million.

The move was driven by a broad rally across the Life Sciences Tools and Services sector, with WUXI XDC up 10.02%, PHARMARON up 9.22%, WUXI BIO up 6.81%, GENSCRIPT BIO up 5.86%, and WUXI APPTEC up 5.73%. On the company level, multiple recent catalysts provided support: the NLRP3 inhibitor ISM8969/HT-001, co-developed with Hengtai Biosciences, received NMPA clinical trial approval for Parkinson's disease treatment. The drug features blood-brain barrier penetration capability, differentiating it from peripherally-restricted competitors. Additionally, JPMorgan initiated coverage with an Overweight rating and a HK$71 target price, providing further valuation support alongside the sector-wide momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115138879?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 13:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115138879","market":"hk","top_or_hot":-1,"title":"Movement Alert｜INSILICO Rises 5.61% in Regular Trading, Life Sciences Sector Rally and Positive Pipeline Catalysts Boost Shares","media":"Market Focus","content":"<p><p>On August 7, INSILICO rose 5.61% in regular trading, trading at HK$43.5/share, with turnover of HK$325 million.</p><p>The move was driven by a broad rally across the Life Sciences Tools and Services sector, with WUXI XDC up 10.02%, PHARMARON up 9.22%, WUXI BIO up 6.81%, GENSCRIPT BIO up 5.86%, and WUXI APPTEC up 5.73%. On the company level, multiple recent catalysts provided support: the NLRP3 inhibitor ISM8969/HT-001, co-developed with Hengtai Biosciences, received NMPA clinical trial approval for Parkinson's disease treatment. The drug features blood-brain barrier penetration capability, differentiating it from peripherally-restricted competitors. Additionally, JPMorgan initiated coverage with an Overweight rating and a HK$71 target price, providing further valuation support alongside the sector-wide momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INSILICO Rises 5.61% in Regular Trading, Life Sciences Sector Rally and Positive Pipeline Catalysts Boost Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INSILICO Rises 5.61% in Regular Trading, Life Sciences Sector Rally and Positive Pipeline Catalysts Boost Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 13:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, INSILICO rose 5.61% in regular trading, trading at HK$43.5/share, with turnover of HK$325 million.</p><p>The move was driven by a broad rally across the Life Sciences Tools and Services sector, with WUXI XDC up 10.02%, PHARMARON up 9.22%, WUXI BIO up 6.81%, GENSCRIPT BIO up 5.86%, and WUXI APPTEC up 5.73%. On the company level, multiple recent catalysts provided support: the NLRP3 inhibitor ISM8969/HT-001, co-developed with Hengtai Biosciences, received NMPA clinical trial approval for Parkinson's disease treatment. The drug features blood-brain barrier penetration capability, differentiating it from peripherally-restricted competitors. Additionally, JPMorgan initiated coverage with an Overweight rating and a HK$71 target price, providing further valuation support alongside the sector-wide momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1115138879","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115138879","pubTimestamp":1786079065,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, INSILICO rose 5.61% in regular trading, trading at HK$43.5/share, with turnover of HK$325 million.The move was driven by a broad rally across the Life Sciences Tools and Services sector,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"走势警报|INSILICO 常规交易中上涨 5.61%，生命科学板块反弹和积极的管道催化剂提振股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"On August 7, INSILICO rose 5.61% in regular trading, trading at HK$43.5/share, with turnover of HK$325 million.The move was driven by a broad rally across the Life Sciences Tools and Services sector, with WUXI XDC up 10.02%, PHARMARON up 9.22%, WUXI BIO up 6.81%, GENSCRIPT BIO up 5.86%, and WUXI APPTEC up 5.73%. On the company level, multiple recent catalysts provided support: the NLRP3 inhibitor ISM8969/HT-001, co-developed with Hengtai Biosciences, received NMPA clinical trial approval for Parkinson's disease treatment. The drug features blood-brain barrier penetration capability, differentiating it from peripherally-restricted competitors. Additionally, JPMorgan initiated coverage with an Overweight rating and a HK$71 target price, providing further valuation support alongside the sector-wide momentum.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115138879","isCrawlerRequest":true}